|
WO2020243546A1
|
|
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
|
WO2020181164A1
|
|
Compositions and methods for treating cancer with self-driving chimeric antigen receptors
|
|
WO2020113108A1
|
|
Compositions and methods for treating cancer with anti-cd38 immunotherapy
|
|
WO2020069184A2
|
|
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
|
US2020079849A1
|
|
Chimeric Antigen Receptors and Methods of Use
|
|
CA3113058A1
|
|
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
|
EP3703711A1
|
|
Compositions and methods for treating cancer with anti-ror1 immunotherapy
|
|
CN111629735A
|
|
Compositions and methods for treating cancer with anti-CD22 immunotherapy
|
|
CN111936510A
|
|
Compositions and methods for treating cancer with anti-CD 19 immunotherapy
|
|
EP3661964A1
|
|
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
|
CA3066953A1
|
|
Human monoclonal antibodies specific for cd33 and methods of their use
|
|
CN110997719A
|
|
Compositions and methods for treating cancer with anti-CD 33 immunotherapy
|
|
US2019241641A1
|
|
Compositions and Methods for Treating Cancer with DuoCARs
|
|
US2019134091A1
|
|
Method to treat cancer with engineered T-cells
|
